Korea-made leukemia drug to hit the market

Home > National > Social Affairs

print dictionary print

Korea-made leukemia drug to hit the market

South Korea’s public health and safety agency said yesterday that it has approved the use of a locally developed anti-leukemia drug to better help people combat the potentially fatal disease.

The drug called Supect made by Il-Yang Pharmaceutical Co. has been cleared for use after undergoing clinical tests in the country and in India and Thailand, said the Korea Centers for Disease Control and Prevention (KCDC). Sales will begin in the first half of this year and the drug will compete with drugs made by U.S. and European pharmaceutical companies, it said.

Supect, made from radotinib, is the first anti-leukemia drug made in Asia and approved for use, and is the 18th new medical compound developed in the country.

“It will be used on patients who have become resistant to existing drugs such as Gleevec, Tasigna and Sprycel,” the KCDC said. “The drug can also be administered to people who are non-responsive to current drugs based on such materials as imatinib, nilotinib and dasatinib.”

Extensive tests have shown Supect having fewer side effects than Gleevec, which is marketed by Swiss pharmaceutical firm Novartis, the center said, adding the new drug is safer and causes no problems such as cardiotoxicity and pulmonary edema.

Il-Yang said it has started additional clinical tests in 20 Asian countries such as Korea, India, Thailand and Indonesia. The Seoul-based company said that Supect will be cheaper than existing drugs and should be able to compete effectively for the $5 billion global market. Of the total, the Asian market provides 60 percent of the demand, with an average of 300 Koreans diagnosed with the disease every year.


Yonhap

More in Social Affairs

Civic group sues Seoul gov't to stop Gwanghwamun project

Emissions check

Injunction gives Yoon his job back, at least temporarily

New virus cases stay below 500, but officials say surge isn't over

[Shifting the paradigm] Academia faces brave new world

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now